Lexatumumab

Lexatumumab
Chemical nomenclature
IUPAC name	Immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, Apo-2 antigen)) (human monoclonal HGS-ETR2 heavy chain), disulfide with human monoclonal HGS-ETR2 κ-chain, dimer
Routes	Intravenous
Legal status	Investigational

Lexatumumab is a human monoclonal antibody designed for the treatment of tumors. It targets the TRAIL receptor 2 (also known as DR5 or death receptor 5), which is a member of the tumor necrosis factor (TNF) receptor superfamily. Lexatumumab is classified as a TRAIL receptor agonist.

Mechanism of Action

Lexatumumab binds to the TRAIL receptor 2 on the surface of cancer cells, which activates the receptor's apoptotic pathway. This leads to the induction of programmed cell death, or apoptosis, in the tumor cells. The activation of this pathway is selective for cancer cells, sparing most normal cells, which makes TRAIL receptor agonists a promising therapeutic approach in oncology.

Clinical Trials

Lexatumumab has been evaluated in several clinical trials for its effectiveness and safety in treating various types of cancers, including non-small cell lung cancer, colorectal cancer, and Hodgkin's lymphoma. The trials have focused on assessing the drug's efficacy both as a monotherapy and in combination with other chemotherapeutic agents.

Development and Regulatory Status

As of the last update, lexatumumab is still in the investigational stages and has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. It is currently under development by Human Genome Sciences, Inc.

Potential and Challenges

While lexatumumab has shown potential in preclinical and early clinical studies, the development of TRAIL receptor agonists faces several challenges. These include the variability in response among patients and the potential development of resistance to the therapy. Further research is needed to fully understand the mechanisms of action, optimize dosing regimens, and identify patient populations that might benefit the most from this treatment.

See Also

• Monoclonal antibodies
• Apoptosis
• Cancer therapy